

European Society of Endocrinology

Company Limited by Guarantee

FINANCIAL STATEMENTS

31 December 2016

Company Registration Number: 05540866

Charity number: 1123492

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE**

FINANCIAL STATEMENTS

YEAR ENDED 31 December 2016

CONTENTS	PAGE
Reference and administrative details	1
Trustees Annual Report	2
Independent Auditor's report to the Members	15
Statement of Financial Activities (incorporating the income and expenditure account)	17
Balance sheet	18
Statement of cash flows	19
Notes to the financial statements	20

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
REFERENCE AND ADMINISTRATIVE DETAILS**

Registered charity name	European Society of Endocrinology
Charity registration number	1123492
Company registration number	05540866
Registered office	Euro House 22 Apex Court Bradley Stoke Bristol BS32 4JT
Senior Management Team	Helen Gregson – Chief Executive Officer

THE TRUSTEES

The trustees who served the charitable company during the period and up to the date of this report were as follows:

Professor J Bertherat
Professor J Bollerslev
Professor G Brabant
Professor M Korbonits
Professor V Popovic-Brkic
Professor M Simoni
Professor AJ van der Lely
Professor S Webb
Professor O Yildiz
Professor C Schalin-Jantti (appointed 31 May 2016)
Professor M Pfeifer (retired 31 May 2016)
Professor R Ross (retired 31 May 2016)

Secretary	Divinerule Limited
Auditor	Moore Stephens LLP Chartered Accountants Statutory Auditor 35 Calthorpe Road Birmingham, B15 1TS.
Investment managers	Until June 2016 HSBC Global Asset Management 78 St James's Street London, SW1A 1HL From July 2016 Charles Stanley & Co 55 Bishopsgate London, EC2N 3AS

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT - YEAR ENDED 31 DECEMBER 2016**

The trustees have pleasure in presenting their report and the financial statements of the charity for the year ended 31 December 2016.

INTRODUCTION

The European Society of Endocrinology (“the Society” or “ESE”) is a charity and a company limited by guarantee. Its members are scientists, physicians and students with an involvement in endocrinology.

The Society’s beneficiaries are its members, students, endocrine patients, and the general public. The Society provides a range of public benefits aimed at providing educational and research support to these groups and these benefits are detailed in this report.

Endocrine disorders are very common and it is likely that over half of the population will suffer from one at some point in their lives. For example, about a third of women and almost twenty percent of men over the age of 50 will have an osteoporotic fracture at some point in their lifetime. One in ten women of reproductive age have polycystic ovary syndrome and a similar proportion of women over 65 have mild hypothyroidism. Diabetes is a public health issue estimated to affect 6.4% (285 million) people worldwide in 2010 and forecast to rise to 7.7% (438 million) in 2030. Type-2 accounts for more than 90% of all patients with diabetes. People with diabetes have an up to fivefold increased risk of cardiovascular disease compared with those without diabetes.

In addition, there are a large number of rarer endocrine conditions, including for example Cushing’s disease, acromegaly, multiple endocrine neoplasia and congenital adrenal hyperplasia.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Society was incorporated on 18 August 2005, and commenced activities on 1 January 2006. The organisation was registered as a charity on 8 April 2008 and these accounts have therefore been audited as a charitable organisation.

Individuals, national endocrine societies in Europe and in countries bordering the Mediterranean Sea, as well as pan-European and international sub-specialist endocrine societies and companies with a focus on endocrinology can be members. The Society values its links with the 47 national endocrine societies and 11 specialist societies that are members, and they also have voting rights, alongside the individual members. Individual membership is open to members of a national medical or scientific society in endocrinology or a related subject. Companies do not have voting rights. In addition, societies outside of Europe can be members as part of the Associate membership scheme.

The Society is governed by the Executive Committee which comprises of not less than ten or more than fifteen members and can include up to three ex-officio members. Ex-officio members have no vote and are not directors of the Society. There is currently an ex-officio member representing endocrine nurses and an ex-officio member representing the ESE Council of Affiliated Societies (ECAS) on the Executive Committee, and in 2016 an ex-officio member representing the European Young Endocrine Scientists (EYES) was introduced.

All applications for individual membership are formally approved by the ESE Executive Committee. There is also an honorary membership category, for people with a special distinction in endocrinology or who have performed outstanding service to the Society. These are nominated through and approved by the Executive Committee.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT (CONTINUED)**

Any Ordinary Member may nominate one other Ordinary Member for vacant Executive Committee positions. There are four Officers on the Executive Committee, namely the President, Vice-President, Secretary and Treasurer. Executive Committee members serve a four-year term, but the Treasurer's and Secretary's positions can be extended for up to two years subject to approval of the General Council.

In 2017, the position of President-elect will be introduced in place of the Vice President role. The President-elect term of office is for two years and then as President for a further two years.

In 2016 the Society had nine committees. The committees report to the Executive Committee through their chairman. The committee chairs are appointed by the Executive Committee. Each committee has a remit which has been approved by the Executive Committee. The committees are:

Clinical Committee
Congress Committee
Education Committee
European Young Endocrine Scientists (EYES) Committee
Finance Committee (discontinued in November 2016)
International Liaison Committee
Nominations Committee
Publishing and Communications Committee
Science Committee

In addition to the Committees, the ESE Nurses' Working Group reports to the Clinical Committee. The chair of the working group, Sofia Llahana, is an ex-officio member of the Executive Committee. The IESP Selection Panel reports to the Science Committee.

The ESE Council of Affiliated Societies provides a collaborative network to enhance the visibility of endocrine research, development and education across Europe. ECAS membership comprises 47 national endocrine societies, represented at ECAS meetings typically through their President or Secretary. An ECAS representative is nominated and voted for by the ECAS members and is an ex-officio member of the Executive Committee. This representative is responsible for liaising with the ESE office on ECAS activities and meetings.

The European Society of Endocrinology raises its funds mainly through income from its congress, the *European Journal of Endocrinology* and individual and corporate membership subscriptions. The Society also receives some pharmaceutical support through receipt of grants for certain activities.

OBJECTIVES AND ACTIVITIES

The objects of ESE are to promote for the public benefit research, education, and clinical practice in endocrinology by the organisation of conferences, training courses and publications, by raising public awareness, liaison with national and international legislators, and by any other appropriate means.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT (CONTINUED)**

Major areas of activity in support of these objectives

Conferences, training courses and other meetings

The Society runs an annual congress called the European Congress of Endocrinology, which typically attracts around 2500-3000 delegates, comprising basic scientists, clinicians and nurses from throughout Europe and beyond. At this congress details of current research and clinical practice are presented, with the aim of improving scientific research, patient care and clinical practice for the public benefit. The abstracts from the congress are available free of charge on the website. ESE takes full financial responsibility for the congress, and this requires the maintenance of a reserve to support any years in which the meeting may not be successful.

The Society also runs regular postgraduate educational courses aimed at both basic scientists and clinicians and clinical update courses aimed at young and senior endocrinologists. In addition, ESE provides financial support and endorsement for other meetings, in collaboration with other organisations.

Website

The Society runs an active website. The website publicises worldwide events in endocrinology and related areas, and advertises current grants. The website has an online membership directory, which facilitates cross-boundary research collaboration and the sharing of good practice in patient care, thus providing public benefit. The website is also active in advising members and non-members of the latest news stories related to endocrinology and related areas. All the plenary and prize lectures from the annual European Congress of Endocrinology are available to view from the ESE and Congress website. An online forum especially for the European Young Endocrine Scientists (EYES) is available through the ESE website, although this will be discontinued in 2017 and an alternative platform will be identified. The forum provides a platform where early-career endocrinologists, hormonologists, basic researchers and clinicians involved in endocrine research can communicate and share information and participate in and contribute to the EYES community.

The website address is www.ese-hormones.org. The website is also actively used to publicise the activities of its member societies. ESE is currently redeveloping its website so that it better serves its members and endocrinologist worldwide. The new website will be launched in the autumn of 2017.

Journal

The Society owns the *European Journal of Endocrinology*, a respected clinical and translational peer-reviewed publication. The journal publishes original research papers, reviews, and case reports within all areas of endocrinology, thus improving public education. This journal is purchased by institutions and individuals around the world and is available in print and electronic formats. The journal has a separate reserve policy, which is detailed later in the report. Free online access to all papers is available to all ESE current members.

The Society has three other official journals, *Journal of Endocrinology*, *Journal of Molecular Endocrinology* and *Endocrine-Related Cancer*. These journals are also purchased by institutions and individuals around the world and are available in print and electronic formats. Submitted papers that have been accepted are published online within twenty-four hours of acceptance as Accepted Preprints. The abstracts of all material published are available to the public free of charge on the website, as is the full text of review and commentary articles, of all articles published more than 12 months ago, and of articles for which an Open Access fee has been paid.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT (CONTINUED)**

The Society also co-owns *Endocrine Connections*, which is an Open Access journal offering authors the highest possible visibility for their work and stimulating cross-discipline collaboration. *Endocrine Connections* publishes original quality research in all areas of endocrinology, with a focus on papers that have relevance to its related and intersecting disciplines and the wider biomedical community. The journal considers basic, translational and clinical studies.

In addition, in May 2016 ESE agreed a formal collaboration on *Endocrinology, Diabetes and Metabolism Case Reports* (EDMCR), which is an online only, open-access information resource designed to further both medical education and clinical practice by publishing and linking together case reports on common and rare conditions in all areas of clinical endocrinology, diabetes and metabolism. EDMCR is owned by Bioscientifica.

Media Office

The ESE Media Office continues to handle press enquiries throughout the year, as well as identifying key research at the annual congress for press publication. This aims to raise the profile of endocrinology with the public. ESE also runs social media, and it is now running both Facebook and Twitter channels to ESE members and the general public with additional opportunities to find out about its work.

Newsletter

The Society produces a tri-annual newsletter, which ensures that members are informed about the Society's latest activities. The newsletters are available free online and advertise grants and prizes and educational opportunities such as the training courses and congresses, as well as current Society activities and broader information about endocrinology. An additional supplement to the newsletter has been developed, *ESE Insight*, with the aim of delivering additional in-depth content which would be of interest to the ESE membership.

Awards and Prizes

The European Society of Endocrinology recognises world-leading scientists and clinicians through the presentation of our prestigious prizes. The recipient receives their prize at the annual European Congress of Endocrinology where they are also invited to present one of the plenary lectures.

- Geoffrey Harris Prize, generously supported by Ipsen, which is awarded to an established researcher in the field of neuroendocrinology; in 2016 this was awarded to Professor Albert Beckers at the annual European Congress of Endocrinology (ECE).
- *European Journal of Endocrinology* Prize which is awarded to a candidate who has significantly contributed to the advancement of knowledge in the field of endocrinology through publication; in 2016 this was awarded to Professor Jason Carroll at the annual European Congress of Endocrinology (ECE).
- European Hormone Medal which is awarded to an international scientist who has made significant contributions to the field of basic or clinical endocrinology; in 2016 the medal was presented to Professor Felipe Casanueva.
- The Clinical Endocrinology Trust (CET) Award is awarded for clinical research that addresses aspects of endocrinology at the forefront of clinical practice; in 2016 this was awarded to Professor Wiebke Arlt.

In addition to the prizes above, the Society awards a number of grants as follows:

There are 100 ESE Meeting Grants available for ESE members who are within ten years post-PhD or MD or below high income country status as classified by the World Bank. Applicants must be the presenting author of an accepted abstract if attending the ECE. The grant is for use towards the total cost of attending any ESE meeting.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT (CONTINUED)**

The Society is also keen to bring basic scientists to its annual ECE and offers 100 ESE Basic Science Meeting Grants per year worth up to €450 each for ESE members who are basic scientists, are within 10 years post-PHD or MD or from a country below high income country status, as classified by the World Bank and is the presenting author of an accepted abstract. The grant can be used for payment towards travel, accommodation or registration to the annual ECE. In addition to this *Journal of Endocrinology* travel grants, worth up to €300 each, are available to support ten young scientists to attend the ECE.

The ESE Small Meeting Grant is available to support the development of endocrine education in Europe. The grant is available for non-ESE events, such as a symposium, workshop, conference, training course and includes ESE endorsement of the scientific programme. The maximum value of each grant is €2500.

The ESE Short-Term Fellowship is available in order to fund research visits from one week to three months for early-career ESE members. The objective is to promote scientific collaboration between members of ESE. The ESE Short-Term Fellowships are awarded for exchanges between two laboratories in different countries only and the maximum award amount is €2500.

In addition, eight ESE Poster Prizes, worth €250 each, are awarded to the eight best posters on display at the annual ECE (four clinical and four basic) and twelve ESE Young Investigator Awards worth €1500 are presented to researchers submitting abstracts to the annual congress (basic or clinical) and are based on the achieved abstract scores. Presenting authors must be under 35 at the time of the meeting and a member of ESE.

ESE also supports the ESE International Endocrine Scholars Programme (IESP). The IESP is aimed at promoting the career development of young endocrinologists from around the globe by identifying talented young investigators and offering them an exceptional training experience. The purpose of the programme is to select highly qualified candidates who wish to gain training for a period of 2-3 years in an outstanding laboratory. The training focuses on laboratory-based research. Clinically qualified candidates could have an additional clinical observer status, if relevant; however, clinical training is not part of the programme.

ESE provides funding to support travel costs for preparatory visits and supported a limited number of selected scholars. This consists of an award of €3000 to cover visits to potential host labs. Successful candidates are invited to attend the European Society of Endocrinology's annual meeting. Upon selection as an IESP Scholar, the individual receives free membership to the European Society of Endocrinology for a period of three years. Successful candidates receive counsel through a unique mentoring programme to assist in finding financial support, advice and esteemed training opportunities. After the training, successful candidates are expected to return home taking with them experience and knowledge gained through the programme.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT (CONTINUED)**

Volunteers

The Society's success depends on the time and commitment devoted to it by a body of volunteers, who assist on committees, editorial boards, programme development for meetings, as speakers and chairs, local congress organisation and other activities. The Society is immensely grateful to all these volunteers for their hard work.

The trustees of ESE are aware that the charity may be exposed to various risks which include financial risks, risks to the Society's reputation, risk of breaching charitable trust or other legal requirements and risk of professional liability. The trustees have compiled a risk register to ensure measures are put in place to handle these risks. In addition, ESE has professional indemnity insurance in place.

Reserve fund policy

Income to ESE is mainly generated through membership, corporate supporters, the annual congress and investment income. Income is also generated through the ESE journal *European Journal of Endocrinology*. However, the journal has a separate reserve policy and this is ring-fenced. The EJE reserve policy is stated below followed by the reserve policy for the other activities excluding the journal.

EJE Reserve policy

The Society shall maintain a designated reserve fund for the purposes of developing and supporting the *European Journal of Endocrinology*. The reserve fund shall be derived from the investments and annual surpluses of the *European Journal of Endocrinology* agreed to be made available for this purpose provided that the Society shall have no obligation to add further funds. The ESE Executive Committee shall use its best endeavours to ensure that the reserve fund equals the aggregate of two years' expenditure for the publication of the journal based on the most recent actual expenditure of the journal after allowing for inflation calculated in accordance with the Retail Price Index as varied from time to time. The assets, liabilities and activities of the *European Journal of Endocrinology* are held in a designated fund. At each year-end the reserve for this fund is recalculated and adjusted accordingly.

ESE Reserve policy excluding EJE

The reserve policy takes into consideration the major risks that could face the ESE. These are:

(1) The potential withdrawal of funding from corporate supporters, for whatever reason, e.g., changes in regulations causing restriction on funding. Corporate funding was provided in 2016 for the following activities: overall corporate membership for general support of the Society and its administration; support of the ESE postgraduate courses; support of the Geoffrey Harris prize which was awarded at the annual congress; partial support of the newsletter through support of the newsletter supplement, ESE Insight; support of the ESE Cushings patient registry, ERCUSYN; and support of the congress.

(2) The reduction in size of the ESE annual congress for any reason, e.g., removal of industry support, which would result in a reduction of income from the annual congress, resulting in a significant reduction in overall income to the Society that year, and a smaller reduction in expenditure, resulting in a deficit for that year; an Act of God resulting in a major reduction in delegate and company participation in the annual congress, or cancellation.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT (CONTINUED)**

This reserve policy is designed to allow the ESE to continue running its activities for a two-year period, after which the projects would be re-evaluated depending on the level of success in generating new revenue streams. Allowing for a two-year period of financial difficulty would also help to minimise the risk of compromising the objectives and core activities of ESE. A reduction in the scale of activities has been assumed, but not large-scale cancellation of projects.

Conclusion

Using calculations based on the summary above, the Trustees of ESE consider that the required level of readily useable reserves should be £1.253m (€1.475m) for EJE and £1.930m (€2.272m) for activities excluding EJE. These figures are calculated using the rate of exchange on 31 December 2016. The total of the two reserves is £3.183m (€3.747m) and the current total unrestricted income fund as shown in the audited accounts is £4.122m (€4.853m). There is therefore a surplus above the reserve requirement of £939k (€1.106m). The ESE trustees have gone through a full strategic review and have already distributed surplus within 2016 on ESE activities, and have a strategic plan in place to distribute the remaining surplus.

ACHIEVEMENTS AND PERFORMANCE

▪ *ESE Office and internal structure*

In 2016, the Society underwent substantial changes, appointing its first member of directly employed staff as a Chief Executive Officer. Previously, ESE outsourced all of its activities to Bioscientifica. ESE continues to work closely with Bioscientifica on the delivery of its services across Association Management, Publishing and Events through the contracts which were successfully renegotiated in 2015.

▪ *Strategic review and visual identity*

In 2016, the Society went through an extensive review of its vision, mission and strategy and has clearly defined its priorities. In parallel with this process, ESE reviewed its visual identity, which will be launched in 2017.

The vision of ESE is 'To shape the future of endocrinology to improve science, knowledge and health', and its mission is 'To advance endocrinology. We unite, support and represent our specialty, promoting collaboration and best practice, and enable our community to develop and share the best knowledge in endocrine science and medicine'.

The strategic goals of ESE have been defined as follows and these priorities are supported by a full five-year strategic plan:

- Goal 1: To be at the heart of the endocrine community in Europe, acknowledged as the reference point for endocrine science, knowledge and health
- Goal 2: To provide continuous endocrine related education and training provision for all career stages in clinical practice and basic research
- Goal 3: To foster early-career basic and clinical endocrinologists, creating a dynamic community which will inspire them to become endocrinologists and remain in endocrinology
- Goal 4: To continue to run the leading European endocrine congress, ensuring it is kept current, attractive across the Focus Areas, and viewed as the 'must attend' event for endocrinologists across Europe
- Goal 5: To ensure that ESE is financially sustainable through excellent management of commercial partnerships and a clear business development strategy

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT (CONTINUED)**

▪ *European Reference Network for Rare Endocrine Diseases*

The Society has been integrally involved in supporting, with the European Society for Paediatric Endocrinology (ESPE), the application to the European Commission to establish a European Reference Network for Rare Endocrine Disorders (ENDO-ERN). In December 2016, it was confirmed that the application had been successful. The application was co-coordinated by Alberto Pereira and Olaf Hiort and the network will be formed from more than 70 nationally recognised healthcare centres across Europe.

With a focus on ensuring that high quality expertise in the treatment of rare diseases is provided as close to the patient as possible, these networks will work to share expertise, improve diagnosis, educate care providers, facilitate research and link up with other ERNs with the ultimate goal of improving patient care.

ENDO-ERN serves as an opportunity to advance the treatment of people with rare endocrine conditions while significantly improving the patient experience. With a strong base of collaboration and partnership, the network will span paediatric and adult care ensuring all patients are able to benefit and the lessons learnt will benefit the endocrine community in Europe and beyond.

▪ *Membership and the new National Affiliate Membership Scheme*

In 2016, the National Affiliate Membership Scheme was agreed and introduced for the 2017 membership year. This membership is available to members of ESE's National Affiliated Societies and provides a substantial discount on ESE membership fees. This discount was provided as part of the ESE Council of Affiliated Societies ongoing efforts to bring greater collaboration between ESE and the national endocrine societies of Europe.

There was no increase in the annual membership fee in 2016 and the Society also provides the opportunity for members to pay a discounted membership rate for 3-year membership and a discounted rate for lifetime membership.

At the time of the audit, 12 April 2017, the membership numbers stand at 3493 for approved Ordinary members (including Honorary Members) – the highest level to date – and 956 of these had benefited from the new National Affiliated Membership scheme.

In addition to this, there were 367 approved 3 year members and 56 approved lifetime members; 58 Affiliated Society Members, made up of 47 national endocrine societies and 11 speciality societies, and 11 Corporate Members. There was also 1 Associate member.

▪ *ESE Recommended Curriculum for Specialisation in Clinical Endocrinology, Diabetes and Metabolism*

In 2016, ESE published the ESE Recommended Curriculum of Specialisation in Clinical Endocrinology, Diabetes and Metabolism, which had been developed in close liaison with the ESE Council of Affiliated Societies. The curriculum aims to address concerns raised by the ESE Council of Affiliated Societies regarding the standardisation of education within the field of clinical endocrinology, diabetes and metabolism across Europe.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT (CONTINUED)**

ESE, in an effort to provide a more consistent pan-European understanding of clinical endocrinology, diabetes and metabolism, has defined within the curriculum the key areas in which a clinical endocrinologist should be expected to have sufficient knowledge and understanding. The curriculum describes the knowledge requirements for clinicians practicing in endocrinology, diabetes and metabolism and is provided as a resource for students to assess their training progress, for education providers in the development of content and, ultimately, for working towards a standard for endocrine education across Europe. To date, the curriculum has been formally endorsed by over 50% of ESE's 48 Affiliated Societies.

▪ *Conferences, training courses and other meetings*

In 2016 ESE held a successful congress in Munich, Germany, with the German Endocrine Society. The meeting attracted 3364 attendees and 1453 abstracts. The meeting generated a donation to the host society of €176,081 which is included within the total congress costs.

Clinical courses

In 2016, ESE held successful postgraduate courses in Opatija, Croatia (25-28 February 2016) and Wrocław, Poland (17-20 November 2016).

ESE continues its collaboration with the Imperial College London Diabetes Centre in Abu Dhabi, where the 7th ESE Clinical Update was held (15-16 January 2016). This course is now firmly established within the annual training programme and is currently organised without financial risk to ESE. The 8th ESE Clinical Update was held in Tallinn, Estonia (14-15 April 2016).

For the third year in a row ESE, together with the Society of Endocrinology and Metabolism of Turkey and the Endocrine Society (USA), organised EndoBridge 2016 (20-23 October 2016) in Antalya, Turkey. The meeting is currently organised without financial risk to ESE and a small surplus is generated.

Basic Science Courses

In addition to the clinical based training courses, and for the seventh year running, ESE continues its collaboration with the German Endocrine Society (DGE) on the Summer School on Endocrinology held in Bregenz, Austria (31 July – 4 August 2016). This Summer School is a long-established training course directed at basic scientists.

For the fifth time, ESE also collaborated on the 41st Symposium on Hormones and Cell Regulation, which was held in Mont St Odile, France (5-8 October 2016).

ESE hosted the ESE Basic Course on Endocrine and Neuroendocrine Cancer (17-19 February 2016), Porto, Portugal where the topic of 'Beyond Structural Genetic Alterations of Oncogenes and Tumour Suppressor Genes' was covered. It is hoped that a similar course will be held every year in a different location across Europe in collaboration with an ESE Affiliated Society Member.

Translational/themed meetings

In Cordoba, Spain, the themed meeting New Frontiers in Obesity Research took place (28-30 November 2016), in collaboration with Fundación para la Investigación Biomédica de Córdoba (FIBICO).

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT (CONTINUED)**

▪ *Publications*

One of the main measures of success of journals is the impact factor, a measure of how often an article is cited by other authors. The latest impact factors are (the previous year in brackets): *European Journal of Endocrinology* is now 3.892 (4.069); the *Journal of Endocrinology's* impact factor is the highest to date at 4.498 (3.718); the *Journal of Molecular Endocrinology's* impact factor is a strong 2.947 (3.081) and the five-year figure is 3.258 and *Endocrine-Related Cancer's* impact factor is a strong 4.472 (4.805) and the five-year figure is 4.845.

In addition to the journals, the ESE Online Reviews Collection is available through the ESE website. All reviews, commentaries and hypothesis articles published in ESE's official journals since the beginning of 2008 have been collated to form the ESE Online Reviews Collection. These full text files are freely available to all.

The ESE journal, *Endocrine Connections*, which is jointly owned with the Society of Endocrinology was listed in the Science Citation Index Expanded (SCIE) in June 2016 and is due to receive its first impact factor in 2017, which is a major milestone.

▪ *Grants*

In 2016, the Society awarded 122 ESE Meeting Grants, 97 Basic Science Meeting Grants (for ECE 2016), 2 ESE IESP Awards, 4 ESE Short-Term Fellowships and 2 ESE Small Meeting Grants.

▪ *Guidelines*

Following the success of the previous clinical guidelines, ESE published 'Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumours' on 1 August 2016 and are due to publish a guideline on Turner Syndrome and one on Aggressive Pituitary Tumours in 2017.

▪ *EU collaborations and Advocacy*

The Society has continued its membership to the Initiative for Science in Europe (ISE) to foster collaborations at an EU level. ISE is an independent platform of European learned societies and scientific organisations whose aim is to promote mechanisms to support all fields of science at this level, involve scientists in the design and implementation of European science policies, and to advocate strong independent scientific advice in European policy making.

In addition, in July 2016 the Society joined the Alliance for Biomedical Research in Europe (Biomed Alliance), which is a non-profit organisation representing leading European research and medical societies uniting more than 400,000 researchers and health professionals. The Biomed Alliance is committed to promoting excellence in European biomedical research and innovation with the goal of improving the health and well-being of all European citizens. As part of this commitment, ESE has signed up to the Biomed Alliance Code of Conduct of healthcare professionals and scientific organisations. The Code of Conduct document sets out core principles to maintain and enhance professional independence, objectivity and scientific integrity.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT (CONTINUED)**

FINANCIAL REVIEW

The net movement in funds for the year to 31 December 2016 shows a decrease of £16,503 from the previous year. The major income streams for the ESE were from individual and corporate memberships, corporate sponsorship of activities and from the *European Journal of Endocrinology*. In addition, ESE received income from its congress in Munich. The major items of expenditure were from support of the various activities, including the annual congress, travel grants, awards and prizes, the newsletter and website, and the *European Journal of Endocrinology*, and continued investment in its new journal *Endocrine Connections*. In addition, ESE had overheads of which the most significant items related to running its secretariat services and its Executive Committee and Committee meetings.

VAT review

During the year ESE was undergoing a VAT investigation through HMRC to ensure that all of the activities were being correctly accounted for. The results of the VAT audit were received in early 2017 and the VAT position as at the 31 December 2016 has been confirmed within these accounts.

INVESTMENT POLICY

The Society holds funds in interest bearing accounts in the UK and Belgium. Investment funds were held at the beginning of the year by HSBC Global Asset Management, however upon closure of this service by HSBC Global Asset Management the funds were withdrawn and a tender process took place to appoint a new investment partner. The successful company was Charles Stanley and at the time of the audit the account with Charles Stanley was in the process of being set up. ESE investment strategy is for a balanced portfolio with a medium-low risk approach. Investments are made with consideration of a 2-5 year timeframe.

PLANS FOR FUTURE PERIODS

In 2017, ESE will further establish its agreed 2017 – 2021 goals, and the implementation of the strategies and tactics to support these. Specific activities and focus are planned are as follows:

- Raising awareness of ESE through an agreed marketing plan encompassing all of ESE’s activities. This will be enhanced through the launch of the new ESE website in Q3 2017.
- Raising standards in endocrinology through the development of a pan-European examination in Endocrinology, Diabetes and Metabolism, to be launched in the spring of 2018. This is being planned in liaison with the European Union of Medical Specialists (UEMS), the Membership of the Royal College of Physicians UK (MRCP), the Society for Endocrinology and the Association of British Clinical Diabetologists.
- Ensuring the European Congress of Endocrinology is viewed as an essential part of the endocrinologists’ annual calendar through a thorough strategic review of the event, implementing recommendations as required.
- Putting foundations in place for financial stability through the appointment of a Director of Commercial Services, whose role will be to ensure this stability of the organisation as it grows and implements the strategy.
- Making ESE even more attractive to join by conducting a review of membership benefits, and focusing on growth of membership across all categories.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT (CONTINUED)**

- Ensuring that ESE is effectively covering the spectrum of topics and needs within endocrinology through the establishment of activities within its defined Focus Areas of:
 - Adrenal and Neuroendocrine Tumours
 - Calcium and Bone
 - Diabetes, Obesity and Metabolism
 - Environment, Society and Governance
 - Interdisciplinary Endocrinology
 - Pituitary and Neuroendocrinology
 - Reproductive Endocrinology
 - Thyroid

PUBLIC BENEFIT

The trustees have considered the Charities Commission’s requirement in respect of Public Benefit. In their view the charity meets, in full, the criteria to satisfy the test.

GOING CONCERN STATEMENT

The directors have a reasonable expectation that the company will continue in operational existence for the foreseeable future, (12 months after the date of this report), and have, therefore used the going concern basis in preparing these financial statements.

POLITICAL DONATIONS

There were no donations were made within the period.

RELATED PARTIES

None of our trustees receive remuneration or other benefits from their work with the charity. During the year trustees received reimbursed expenses from fulfilling their duty but no other related party transactions were reported during the year.

MEMBERS LIABILITY

The company is limited by guarantee and, as such, does not have a share capital. In the event of winding up, each member has guaranteed to contribute to a maximum of £1 to meet the liabilities of the company.

TRUSTEES’ RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS

The charity trustees (who are also the directors of the European Society for Endocrinology for the purposes of company law) are responsible for preparing a trustees’ annual report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the charity trustees to prepare financial statements for each year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing the financial statements, the trustees are required to:

- Select suitable accountancy policies and then apply them consistently;
- Observe the methods and principles in the Charities SORP;
- Make judgements and estimates that are both prudent and reasonable;
- State whether applicable accounting standards and statements of recommended practice have been followed, subject to any departures disclosed and explained in the financial statements.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
TRUSTEES ANNUAL REPORT (CONTINUED)**

TRUSTEES' RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS (CONTINUED)

- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping accounting records that disclose with reasonable accuracy the financial position of the charitable company and ensure that the financial statements comply with the Charities Act 2011, the Companies Act 2006 and the Constitution of the charitable company. The trustees are also responsible for safeguarding the assets of the charitable company and hence take all reasonable steps for the prevention and detection of fraud and any other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

STATEMENT AS TO DISCLOSURE TO OUR AUDITORS

In so far as the trustees are aware at the time of approving our trustees' annual report:

- There is no relevant audit information of which the charitable company's Auditors are unaware
- The trustees have taken all steps that they ought to have taken to make them aware of any relevant audit information and to establish that the Auditors are aware of such information.

This report has been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

This report was approved by the board of directors and trustees on _____ and signed on its behalf by:

Professor AJ van der Lely
President

Professor O Yildiz
Treasurer

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF EUROPEAN SOCIETY OF ENDOCRINOLOGY
YEAR ENDED 31 DECEMBER 2016**

We have audited the financial statements of European Society of Endocrinology for the year ended 31 December 2016 which are set out on pages 17 to 31. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of trustees and auditor

As explained more fully in the Trustees' Responsibilities Statement set out on pages 13 to 14, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's (APB's) Ethical Standards for Auditors.

Scope of the audit of the financial statements

A description of the scope of an audit of financial statements is provided on the Financial Reporting Council's web-site at www.frc.org.uk/auditscopeukprivate.

Opinion on financial statements

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at Year End and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Annual Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Trustees' Annual Report has been prepared in accordance with applicable legal requirements.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF EUROPEAN SOCIETY OF ENDOCRINOLOGY
(CONTINUED)
YEAR ENDED 31 DECEMBER 2016**

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees Annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Nicholas Simkins FCA, *Senior Statutory Auditor*

For and on behalf of Moore Stephens LLP, Statutory Auditor

35 Calthorpe Road
Edgbaston
Birmingham
West Midlands
B15 1TS

Date:

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
STATEMENT OF FINANCIAL ACTIVITIES
(INCORPORATING THE INCOME AND EXPENDITURE ACCOUNT)
YEAR ENDED 31 DECEMBER 2016**

	Note	Total Funds 2016 £	Total Funds 2015 £
INCOME AND ENDOWMENTS FROM:			
Charitable activities	6	2,621,122	2,285,805
Other trading activities	4	279,156	236,850
Investments	5	7,420	10,164
		<hr/>	<hr/>
TOTAL INCOMING RESOURCES		2,907,698	2,532,819
		<hr/>	<hr/>
EXPENDITURE ON:			
Raising funds		15,803	20,678
Publicity and awareness	7	89,134	42,706
Charitable activities	8	2,786,230	2,270,550
		<hr/>	<hr/>
TOTAL RESOURCES EXPENDED		2,891,167	2,333,934
		<hr/>	<hr/>
NET INCOME BEFORE INVESTMENT GAINS/(LOSSES)		16,531	198,885
		<hr/>	<hr/>
Gains/(losses) on investment assets	12	(33,034)	110,291
		<hr/>	<hr/>
NET (OUTGOING)/INCOMING RESOURCES FOR THE YEAR	10	(16,503)	309,176
		<hr/>	<hr/>
NET MOVEMENT IN FUNDS FOR THE YEAR		(16,503)	309,176
RECONCILIATION OF FUNDS			
Total funds brought forward		4,138,116	3,828,940
		<hr/>	<hr/>
TOTAL FUNDS CARRIED FORWARD		4,121,613	4,138,116
		<hr/> <hr/>	<hr/> <hr/>

The Statement of Financial Activities includes all gains and losses recognised in the year.

All incoming resources and resources expended derive from continuing activities.

The notes on pages 20 to 31 form part of these financial statements.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE
BALANCE SHEET
As at 31 DECEMBER 2016**

	Note	2016 £	£	2015 £
FIXED ASSETS				
Investments	12		-	1,697,776
CURRENT ASSETS				
Debtors	13	1,562,483		1,049,545
Cash at bank		3,506,540		1,807,946
		<u>5,069,023</u>		<u>2,857,491</u>
CREDITORS: Amounts falling due within one year	14	(947,410)		(417,151)
				<u>2,440,340</u>
NET CURRENT ASSETS			4,121,613	
				<u>4,138,116</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			4,121,613	4,138,116
				<u>4,138,116</u>
NET ASSETS			4,121,613	4,138,116
				<u>4,138,116</u>
FUNDS				
Unrestricted income funds	15		4,121,613	4,138,116
				<u>4,138,116</u>
TOTAL FUNDS			4,121,613	4,138,116
				<u>4,138,116</u>

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

These financial statements were approved by the members of the committee on _____, 2017 and are signed on their behalf by:

Professor AJ van der Lely
President

Professor O Yildiz
Treasurer

Company Registration Number: 05540866

The notes on pages 20 to 31 form part of these financial statements.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE**

**STATEMENT OF CASH FLOWS
YEAR ENDED 31 DECEMBER 2016**

		2016	2015
		£	£
Cash flows from operating activities	20	(189,103)	534,746
Cash flows from investing activities	21	1,887,697	265,528
Change in cash in the year		1,698,594	800,274
Cash at the beginning of the year		1,807,946	1,007,672
Cash at the end of the year		3,506,540	1,807,946

The notes on pages 20 to 31 form part of these financial statements.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE**

**NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2016**

1. CHARITABLE COMPANY INFORMATION

The European Society of Endocrinology is a private limited charitable company limited by guarantee by not having any share capital incorporated and domiciled in England and Wales. The registered office is Euro House, 22 Apex Court, Bradley Stoke, Bristol, BS32 4JT.

2. ACCOUNTING POLICIES

Basis of accounting

The financial statements have been prepared under the historical cost convention, as modified by the revaluation of certain fixed assets, and in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) (effective 1 January 2015), the Charities Act 2011 and the Companies Act 2006.

The company constitutes a public benefit entity as defined by FRS 102.

The financial statements are prepared in Sterling and rounded to the nearest £1.

Preparation of the accounts on a going concern basis

Having assessed the charitable company's financial position and plans for the foreseeable future the Trustees are satisfied that it remains appropriate to prepare the financial statements on a going concern basis.

Fixed asset investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing market value. Gains and losses arising on disposals and revaluation throughout the year are included in the statement of financial activities.

All gains and losses are taken to the Statement of Financial Activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE**

**NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2016 (CONTINUED)**

2. ACCOUNTING POLICIES (CONTINUED)

Incoming resources

All income is recognised once the charity has entitlement to the funds, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donations and grants are accounted for on a receivable basis, where the receipt is probable and can be measured reliably.

Publications income, sponsorships, membership subscriptions and investment income are accounted for in the period they relate on an accruals basis

Resources expended

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs are allocated or apportioned to the applicable expenditure headings.

Support costs represent the indirect costs incurred in providing support for all activities of the charity. Irrecoverable VAT has also been included as a support cost. These have been allocated on the basis of the direct costs of the relevant activity.

Expenditure is charged as a cost net of VAT against the activity for which the expenditure was incurred.

Debtors

Trade debtors are measured at transaction price, less any impairment.

Cash at bank

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less.

Creditors

Short term creditors are measured at transaction price and are recognised where the charity has a present obligation resulting from a past event that would probably result in a transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE**

**NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2016**

2. ACCOUNTING POLICIES (continued)

Financial instruments

The company enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade debtors and trade creditors.

Debt instruments (other than those wholly repayable or receivable within one year) are initially measured at the present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently at the undiscounted amount of the cash or other consideration expected to be paid or received.

Pensions

The company operates a defined contribution plan for its employees. A defined contribution pension plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations.

The contributions are recognised as an expense in the Statement of Financial Activities when they fall due. Amounts not paid are shown as a liability in the Balance Sheet. The assets of the plan are held separately from the company in independently administered funds.

Foreign currencies

The company's functional currency is Euros and presentational currency is GBP.

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transaction.

At each period end foreign currency monetary items are translated using the closing rate.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the statement of financial activities.

Fund accounting

Unrestricted funds comprise those funds which the trustees are free to use in accordance with the charitable objects.

Designated funds comprise unrestricted funds that have been set aside by the trustees for particular purposes.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE**

**NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2016**

NOTES (CONTINUED)

**3. JUDGEMENTS IN APPLYING ACCOUNTING POLICIES AND KEY SOURCES OF ESTIMATION
UNCERTAINTY**

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The directors do not believe there are any assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

4. INCOMING RESOURCES FROM ACTIVITIES FOR GENERATING FUNDS

	Unrestricted Funds	Total Funds 2016	Total Funds 2015
	£	£	£
Sponsorships	279,156	279,156	236,850

5. INVESTMENT INCOME

	Unrestricted Funds	Total Funds 2016	Total Funds 2015
	£	£	£
Income from non-UK listed investments	7,420	7,420	10,164

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE**

**NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2016**

6. INCOMING RESOURCES FROM CHARITABLE ACTIVITIES

	Unrestricted Funds	Total Funds 2016	Total Funds 2015
	£	£	£
Congress income	1,967,866	1,967,866	1,622,372
Publications income	389,227	389,227	430,646
Membership subscriptions (including Corporate members)	241,534	241,534	232,536
Royalties received	-	-	251
Rebates and commissions	22,495	22,495	-
	<u>2,621,122</u>	<u>2,621,122</u>	<u>2,285,805</u>

7. PUBLICITY AND AWARENESS

	Direct charitable activities	Support costs	Total Funds 2016	Total Funds 2015
	£	£	£	£
Media office and publicity	89,134	-	89,134	42,706
	<u>89,134</u>	<u>-</u>	<u>89,134</u>	<u>42,706</u>

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE**

**NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2016**

8. COSTS OF CHARITABLE ACTIVITIES BY ACTIVITY TYPE

COSTS OF CHARITABLE ACTIVITIES BY ACTIVITY TYPE

	Direct charitable activities	Support costs	Total Funds 2016	Total Funds 2015 – restated
	£	£	£	£
Congress costs	1,294,794	-	1,294,794	1,339,966
Grants, prizes & sponsorships	229,115	-	229,115	193,803
Membership	365,536	4,617	370,153	205,862
Newsletter	95,143	-	95,143	47,724
Annual meetings & events	163,521	-	163,521	169,610
Publications costs	108,708	-	108,708	17,724
Clinical and scientific activities	29,782	-	29,782	41,027
Staff costs	11	-	66,462	-
Office overheads	-	34,273	34,273	-
Donation	132,000	-	132,000	28,550
Foreign exchange losses / (gains)	-	(192,279)	(192,279)	140,192
VAT debtor write off	-	198,513	198,513	-
Governance costs	9	-	256,045	86,091
	<u>2,418,599</u>	<u>367,631</u>	<u>2,786,230</u>	<u>2,270,550</u>

Donation:

In 2016, a donation of £132,000 was generated for the German Endocrine Society, as host Society of ECE 2016, held in Munich. In 2015, a donation of £28,550 was generated for the Irish Endocrine Society, as host Society of ECE 2015, held in Dublin.

VAT debtor write off

Following the conclusion of an HMRC VAT investigation, a historical VAT balance has been written off to ensure the correct VAT balance is included in the balance sheet as at 31 December 2016.

Prior year adjustment

The charity has revised how expenditure is classified within the costs of charitable activity by type note above. There is no change in the total costs for the 2015 year but amounts included within memberships, clinical and scientific activities and governance costs have changed.

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE**

**NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2016**

8. COSTS OF CHARITABLE ACTIVITIES BY ACTIVITY TYPE (CONTINUED)

Grants, prizes and sponsorships:

	2016	2015
	£	£
Geoffrey Harris prize	13,159	12,451
ESE Young Endocrine Scientists (EYES)	13,841	7,299
ESE Young Investigator Awards	14,942	13,078
EJE Prize	4,462	2,143
ESE Meeting grants	35,009	24,727
Poster prizes	1,890	3,381
ESE Small Meeting grants	7,677	7,265
IESP Programme	3,278	12,552
Basic Science Meeting Grants	30,754	25,280
ERCUSYN	91,473	65,212
Short Term Fellowship	6,658	2,344
European Hormone Medal	4,062	5,464
Honorary and special recognition awards	574	452
Nurse activities	1,336	12,155
	<u>229,115</u>	<u>193,803</u>

9. GOVERNANCE COSTS

	Unrestricted Funds	Total Funds 2016	Total Funds – restated 2015
	£	£	£
Audit fees	7,000	7,000	4,950
Legal and professional fees	8,195	8,195	20,217
Costs of trustees' meetings	240,850	240,850	60,924
	<u>256,045</u>	<u>256,045</u>	<u>86,091</u>

10. NET (OUTGOING)/INCOMING RESOURCES FOR THE YEAR

This is stated after charging:

	2016	2015
	£	£
Auditors' fees	7,000	4,950
Foreign exchange losses / (gains)	(192,279)	140,192
	<u> </u>	<u> </u>

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE**

**NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2016**

11. STAFF COSTS AND EMOLUMENTS PARTICULARS OF EMPLOYEES

Number of employees

The average monthly number of employees during the year was:

	2016	2015
	Number	Number
Managerial staff	1	-

Employment costs

	2016	2015
	£	£
Wages and salaries	56,769	-
Social security costs	6,333	-
Other pension costs	3,360	-
Total	66,462	-

There was one employee earning an annual salary of over £60,000 in the current period and falls within the following banding. No employees earned over £60,000 in the 2015 financial year.

Banding	2016	2015
£70,001 – £80,000	1	-

Key management personnel

The key management personnel of the charity comprise the Trustees and the Chief Executive Officer. The total employee benefits of the key management personnel of the charity were £60,129 (2015: £Nil).

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE**

**NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2016**

12. INVESTMENTS

Movement in market value

	2016	2015
	£	£
Market value at 1 January 2016	1,697,776	2,101,443
Additions at cost	109,882	549,478
Disposals	(1,990,159)	(804,842)
Foreign exchange adjustment	215,535	(258,594)
Net gains /(losses) on revaluations in the year ended 31 December 2016	(33,034)	110,291
	<u>-</u>	<u>1,697,776</u>
Market value at 31 December 2016	<u>-</u>	<u>1,697,776</u>
	<u>-</u>	<u>1,753,919</u>
Historical cost at 31 December 2016	<u>-</u>	<u>1,753,919</u>

Analysis of investments at 31 December 2016 between funds

	Total Funds 2016	Total Funds 2015
	£	£
Listed investments		
UK Quoted Shares	-	182,414
Non-UK Quoted Shares	-	1,515,362
	<u>-</u>	<u>1,697,776</u>
	<u>-</u>	<u>1,697,776</u>

13. DEBTORS

	2016	2015
	£	£
Trade debtors	1,058,306	716,563
Other debtors	22,582	178,158
Prepayments	481,595	154,824
	<u>1,562,483</u>	<u>1,049,545</u>
	<u>1,562,483</u>	<u>1,049,545</u>

EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2016

14. CREDITORS: Amounts falling due within one year

	2016	2015
	£	£
Other creditors	719,118	255,856
Accruals and deferred income	228,292	161,295
	<u>947,410</u>	<u>417,151</u>

Deferred income comprises amounts received in advance in respect of the 2016 Congress of £223,550 (2015: £161,295) and corporate membership fees of £4,742 (2015: £nil).

15. UNRESTRICTED INCOME FUNDS

	Balance at 1 January 2016 £	Incoming resources £	Outgoing resources £	Gains and (losses) £	Interfund transfer £	Balance at 31 December 2016 £
General fund	2,936,116	2,518,471	(2,782,459)	-	196,485	2,868,613
Designated fund	1,202,000	389,227	(108,708)	(33,034)	(196,485)	1,253,000
	<u>4,138,116</u>	<u>2,907,698</u>	<u>(2,891,167)</u>	<u>(33,034)</u>	<u>-</u>	<u>4,121,613</u>

The designated fund is in relation to the development and support of the *European Journal of Endocrinology*.

16. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Investments £	Net current assets/ (liabilities) £	Total £
Unrestricted Income Funds	-	2,868,613	2,868,613
Designated Fund	-	1,253,000	1,253,000
	<u>-</u>	<u>4,121,613</u>	<u>4,121,613</u>

Analysis of net assets between funds – previous year

	Investments £	Net current assets/ (liabilities) £	Total £
Unrestricted Income Funds	-	2,936,116	2,936,116
Designated Fund	1,697,776	(495,776)	1,202,000
	<u>1,697,776</u>	<u>2,440,340</u>	<u>4,138,116</u>

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE**

**NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2016**

17. RELATED PARTY TRANSACTIONS

No transactions with related parties were undertaken such as are required to be disclosed under FRS 102.

18. COMPANY LIMITED BY GUARANTEE

The company is limited by guarantee and, as such, does not have a share capital. In the event of winding up, each member has guaranteed to contribute to a maximum of £1 to meet the liabilities of the company.

19. TRUSTEES

None of the trustees (or any persons connected with them) received any remuneration during the year or previous accounting period.

ESE currently has 11 trustees. ESE makes every attempt to minimise the costs of the Executive Committee meetings, by holding them at training courses or congresses where the trustees are already present. In addition, Committees of ESE carry out their businesses where possible by email, phone or by meeting at a training course or congress where the members are already present. In 2016 the trustees' expenses wholly attributable to committee business was £12,987 (2015: £7,460).

20. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2016	2015
	£	£
Net movement in funds	(16,503)	309,176
Investment income	(7,420)	(10,164)
(Gains)/losses on investments	33,034	(110,291)
Foreign exchange (gains)/losses on investments	(215,535)	258,594
Decrease/(increase) in debtors	(512,938)	(75,561)
Increase/(decrease) in creditors	530,259	162,992
	<hr/>	<hr/>
Net cash used in operating activities	(189,103)	534,746
	<hr/> <hr/>	<hr/> <hr/>

**EUROPEAN SOCIETY OF ENDOCRINOLOGY
COMPANY LIMITED BY GUARANTEE**

**NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31 DECEMBER 2016**

21. CASH FLOWS FROM INVESTING ACTIVITIES

	2016	2015
	£	£
Investment income	7,420	10,164
Purchase of investments	(109,882)	(549,478)
Proceeds of sale of investments	1,990,159	804,842
	<hr/>	<hr/>
Net cash used in operating activities	1,887,697	265,528
	<hr/> <hr/>	<hr/> <hr/>

22. DEFINED CONTRIBUTION PENSION SCHEME

The charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. The pension charge represents contributions payable by the charity to the fund and amounted to £3,360 (2015: £Nil). Contributions totalling £Nil (2015: £Nil) were payable to the fund at the balance sheet date.

23. FINANCIAL INSTRUMENTS

	2016	2015
	£	£
Financial assets measured at fair value	3,506,540	1,807,946
Financial assets measured at amortised costs	1,088,888	894,721
	<hr/>	<hr/>
	4,587,428	2,702,667
	<hr/> <hr/>	<hr/> <hr/>
Financial liabilities measured at amortised costs	719,188	255,856
	<hr/>	<hr/>
	719,188	255,856
	<hr/> <hr/>	<hr/> <hr/>

Financial assets measured at fair value costs of cash at bank.

Financial assets measured at amortised cost consist of trade debtors and other debtors.

Financial liabilities measured at amortised cost consist of other creditors.

These pages do not form part of the financial statements

European Society of Endocrinology Company Limited by Guarantee
Detailed income and expenditure account.
Year ended 31 December 2016

	Year to 31 Dec 16 £	Year to 31 Dec 15 £
Income		
Membership Subscriptions (including Corporate Members)	241,534	232,536
2016 Congress income (comparative 2015)	1,967,866	1,622,372
Sponsorship:		
Website	-	-
Courses	121,217	112,612
Prizes	16,583	10,898
ERCUSYN database	36,948	79,919
ESE Insight	104,408	33,421
Educational grant	-	-
	<hr/>	<hr/>
	279,156	236,850
Royalties	-	251
Publications income	389,227	430,646
Rebates and commissions	22,495	-
	<hr/>	<hr/>
	2,900,278	2,522,655
Direct costs		
Newsletter expenditure	95,143	47,724
Publications expenditure	108,708	17,724
EJE Prize	4,462	2,143
ESE Young Investigator Awards	14,942	13,078
Geoffrey Harris Prize	13,159	12,451
2016 Congress costs (comparative 2015)	1,294,794	1,339,966
ESE Courses	163,525	169,610
Website costs	52,505	6,176
Publicity/media office	89,134	42,706
ESE Meeting grants	35,009	31,992
ESE Small Meeting grants	7,677	7,265
IESP Programme	3,278	12,552
Basic Science Meeting Grants	30,754	25,280
ESE Young Endocrine Scientists (EYES)	13,841	7,299
Clinical and scientific activities	29,782	41,027
Short Term Fellowship	6,658	2,344
Nurse activities	1,336	12,155
ERCUSYN	91,473	65,212
Other grants	6,527	-
Investment manager costs	15,803	20,678
Other meetings expenses	5,297	3,032
VAT debtor write off	198,513	-
	<hr/>	<hr/>
	2,282,320	1,880,414
Gross surplus	617,958	642,241

European Society of Endocrinology. Company Limited by Guarantee.
Detailed income and expenditure account continued
Year ended 31 December 2016

Overheads

Administration running costs	1,251	2,467
Executive Committee/Trustee meetings	240,850	60,924
Legal and professional	8,195	20,217
Secretariat Services	313,030	178,897
Auditor's remuneration	7,000	4,950
Bank charges	(1,936)	17,323
Foreign currency losses / (gains)	(192,278)	140,192
Payroll costs	66,462	-
Office overheads	34,273	-
Donation LOC – 2016 Congress (2015 Congress)	132,000	28,550
	608,847	453,520
Operating surplus / (deficit)	9,111	188,721
Investment income	7,420	10,164
Surplus / (deficit) on ordinary activities	16,531	198,885

European Society of Endocrinology Company Limited by Guarantee.
Detailed income and expenditure account.
Year ended 31 December 2016

	Year to 31 Dec 16 €	Year to 31 Dec 15 €
Income		
Membership Subscriptions (including Corporate Members)	298,887	320,063
2016 Congress income (comparative 2015)	2,435,135	2,233,033
Sponsorship:		
Website	-	-
Courses	150,000	155,000
Prizes	20,520	15,000
ERCUSYN database	45,721	110,000
ESE Insight	129,200	46,000
Educational grant	-	-
	<hr/>	<hr/>
	345,441	326,000
Royalties	-	345
Publications income	481,649	592,742
Rebates and commissions	27,837	-
	<hr/>	<hr/>
	3,588,949	3,472,183
Direct costs		
Newsletter expenditure	117,735	65,687
Publications expenditure	134,520	24,395
EJE Prize	5,522	2,950
ESE Young Investigator Awards	18,490	18,000
Geoffrey Harris Prize	16,284	17,138
2016 Congress costs (congress 2015)	1,602,242	1,844,328
ESE Courses	202,354	233,451
Website costs	64,973	8,500
Publicity/media office	110,299	58,782
ESE Meeting grants	43,322	44,034
ESE Small Meeting grants	9,500	10,000
IESP Programme	4,056	17,277
Basic Science Meeting Grants	38,057	34,795
ESE Young Endocrine Scientists (EYES)	17,128	10,047
Clinical and scientific activities	36,853	56,470
Short Term Fellowship	8,239	3,226
Nurse activities	1,653	16,730
ERCUSYN	113,193	89,758
Other grants	8,077	-
Investment manager costs	19,555	28,462
Other meetings expenses	6,555	4,173
VAT debtor write off	245,650	-
	<hr/>	<hr/>
	2,824,257	2,588,203
Gross surplus	764,692	883,980

European Society of Endocrinology. Company Limited by Guarantee
Detailed income and expenditure account continued
Year ended 31 December 2016

Overheads

Administration running costs	1,554	3,396
Executive Committee/Trustee meetings	298,040	83,856
Legal and professional	10,140	27,827
Secretariat Services	387,360	246,233
Auditor's remuneration	8,662	6,813
Bank charges	(2,396)	23,843
Payroll costs	82,243	-
Office overheads	42,403	-
Donation LOC – 2016 Congress (2015 Congress)	163,343	39,296
	<hr/>	<hr/>
	991,349	431,264
	<hr/>	<hr/>
Operating surplus / (deficit)	(226,657)	452,716
Investment income	9,182	13,990
	<hr/>	<hr/>
Surplus / (deficit) on ordinary activities	(217,475)	466,706
	<hr/> <hr/>	<hr/> <hr/>